QLH11906
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2022
Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1